Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158288 · ClinicalTrials.gov registry record · Phase 2
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
A Phase 2 study of Substance-Related Disorders and Opioid Dependence, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT00158288 is a Phase 2 study of Substance-Related Disorders and Opioid Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 140 participants, below the 1,519-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00158288, a Phase 2 study of Substance-Related Disorders and Opioid Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
Although LAAM, a derivative of methadone, has been successfully used as an alternative to methadone maintenance in opioid addicts, its effect on concurrent opioid and cocaine abuse has not been ascertained. Thus, this study proposes to examine the clinical efficacy of low- and high-dose LAAM maintenance on opioid and cocaine use in opioid-dependent cocaine abusers. In addition, since contingency management procedures have demonstrated some success in decreasing cocaine use in cocaine-abusing individuals, this study also proposes to examine the clinical efficacy of the presence or absence of contingency management procedures targeting illicit drug use.
Conditions Studied
Interventions
- BEHAVIORAL LAAM
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 1997-03 |
| Est. Completion | 2001-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00158288
The ClinicalTrials.gov registry entry for NCT00158288 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,519-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (91% lower). The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which LAAM is the first listed.
NCT00158288 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00158288 about?
NCT00158288 is a clinical study titled "The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1". Although LAAM, a derivative of methadone, has been successfully used as an alternative to methadone maintenance in opioid addicts, its effect on concurrent opioid and cocaine abuse has not been ascertained. Thus, this study proposes to examine the clinical efficacy of low- and high-dose LAAM mainten...
What is the current status of trial NCT00158288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 1997-03. Estimated completion is 2001-08.
What conditions does trial NCT00158288 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid Dependence, Heroin Dependence, Contingency Management, Behavior Therapy.
What interventions are being tested in trial NCT00158288?
The interventions under investigation include: LAAM (BEHAVIORAL).
Who is sponsoring clinical trial NCT00158288?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00158288 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
RECRUITING · Phase 2
-
GLP-1R Agonist Treatment for Opioid Use Disorder
RECRUITING · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
-
Buprenorphine Maintenance for Opiate Dependence - 6
COMPLETED · Phase 2
-
A Laboratory Model for Heroin Abuse Medications - 8
COMPLETED · Phase 2
-
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.